FDA OKs United Imaging’s Breakthrough 5T MRI

United Imaging, a manufacturer of advanced medical imaging and radiotherapy equipment, has obtained U.S. Food and Drug Administration (FDA) clearance for its uMR Jupiter 5T MRI system.
 
uMR Jupiter, according to the company, is the first ultra-high field system cleared for whole body applications. It’s also the first system on the market of any field strength that has an eight-channel, whole-body multi-transmit system.
 
It broadens imaging capabilities to anatomical regions previously challenging on UHF like the heart, abdomen, and pelvis. The breakthrough technology aims to empower radiologists to spot and diagnose conditions with more precision and confidence in a larger variety of exams.
 
The 5T MRI lets clinicians visualize anatomical structures with unprecedented clarity and detail, United Imaging said. It harnesses ultra-high-field (UHF) magnet strength for enhanced resolution and unparalleled signal-to-noise-ratio, the company also claims.
 
Through design and engineering, United Imaging said, uMR Jupiter 5T has mastery over the two hey challenges related to UHF MRI: image uniformity and radiofrequency safety.
 
“For decades, whole body applications above 3T have been elusive, and this system was targeted to open those doors. uMR Jupiter breaks new ground and defines a new technical category of systems, said Dr. Al Zhang, Ph.D., United Imaging’s chairman and co-CEO. “We are excited to be able to discuss this technology at ISMRM with the world.”
 
“Our investments in R&D and in a highly efficient vertical integration strategy for our manufacturing have repeatedly led to breakthroughs—especially ones that help us achieve our mission of Equal Healthcare for All,” added United Imaging North America’s president and chief commercial officer Jeffrey M. Bundy, Ph.D. “We have always prioritized innovation that can make a broad clinical impact. Because it is aimed first and foremost at bringing ultra-high-field into greater clinical use, we believe it will have an exciting impact across our industry, and for clinical patients across the globe who have never had access to ultra-high-field in the past.”